Department of Anesthesiology and Pain Medicine, University of Toronto, 12th Floor, 123 Edward Street, Toronto, ON, M5G 1E2, Canada.
Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
Can J Anaesth. 2023 Aug;70(8):1397-1400. doi: 10.1007/s12630-023-02521-3. Epub 2023 Jun 6.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide are a class of medications prescribed to treat type 2 diabetes mellitus, and more recently, as an adjunct for weight loss because of its effects of delaying gastric emptying and suppressing appetite. Semaglutide is a long-acting agent with a half-life of approximately one week, and there are currently no guidelines that address the perioperative management of such agents.
We describe an unexpected case of regurgitation of a large volume of gastric contents upon induction of general anesthesia in a nondiabetic, nonobese patient despite a long preoperative fasting period (20 hr for solids and eight hours for clear fluids). This patient had no traditional risk factors for regurgitation or aspiration but was taking the GLP-1 RA semaglutide for weight loss and had last taken the medication two days before their scheduled procedure.
Patients taking long-acting GLP-1 RAs such as semaglutide may be at risk of pulmonary aspiration under anesthesia. We propose strategies to mitigate this risk including holding the medication four weeks prior to a scheduled procedure when feasible and considering full stomach precautions.
胰高血糖素样肽-1 受体激动剂(GLP-1 RAs),如司美格鲁肽,是一类用于治疗 2 型糖尿病的药物,最近因其可延缓胃排空和抑制食欲的作用,也被用作辅助减肥药物。司美格鲁肽是一种具有约一周半衰期的长效制剂,目前尚无针对此类药物围手术期管理的指南。
我们描述了一例非糖尿病、非肥胖患者在全身麻醉诱导时出现大量胃内容物反流的意外情况,尽管该患者进行了长时间的术前禁食(固体 20 小时,清水 8 小时)。该患者无反流或误吸的传统危险因素,但因减肥而服用 GLP-1RA 司美格鲁肽,且在预定手术前两天最后一次服用该药。
服用司美格鲁肽等长效 GLP-1RA 的患者在麻醉下可能有发生肺误吸的风险。我们提出了一些策略来降低这种风险,包括在可行的情况下,在预定手术前四周停药,以及考虑全面的胃部预防措施。